AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was the recipient of a significant increase in short interest in July. As of July 14th, there was short interest totalling 7,275,061 shares, an increase of 98.9% from the June 30th total of 3,657,353 shares. Based on an average daily trading volume, of 8,475,366 shares, the days-to-cover ratio is currently 0.9 days. Approximately 8.4% of the company’s stock are sold short.

A number of research analysts have weighed in on the stock. FBR & Co reaffirmed a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Saturday, April 8th. Piper Jaffray Companies set a $2.00 price target on shares of AVEO Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, June 24th. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Monday. Finally, ValuEngine lowered shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 2.45 on Thursday. The stock has a 50 day moving average of $1.85 and a 200-day moving average of $0.98. The company’s market cap is $270.39 million. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $3.19.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). The company had revenue of $2.53 million during the quarter. AVEO Pharmaceuticals had a negative net margin of 728.85% and a negative return on equity of 836.92%. On average, analysts forecast that AVEO Pharmaceuticals will post ($0.39) EPS for the current year.

Hedge funds have recently made changes to their positions in the company. Paloma Partners Management Co bought a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at approximately $184,000. Clear Harbor Asset Management LLC bought a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at approximately $289,000. UBS Oconnor LLC bought a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at approximately $291,000. Sabby Management LLC bought a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at approximately $513,000. Finally, Renaissance Technologies LLC increased its stake in shares of AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 148,500 shares during the period. 50.96% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/07/27/aveo-pharmaceuticals-inc-aveo-short-interest-up-98-9-in-july.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.